Shengjing Hospital: Breast Neoplasms trials

The registry lists 31 Breast Neoplasms studies with Shengjing Hospital as lead sponsor. 23 are open to participants now and 0 have results posted.

Phase 2 12Phase 3 4Phase 4 2No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingNCT07795424Phase 2
• AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast CancerNot yet recruitingNCT07497191
• Predicting Recurrence in HR+/HER2- Early Breast CancerNot yet recruitingNCT07484763
• The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast CancerRecruitingNCT06698679
• The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast CancerRecruitingNCT06690645
• SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast CancerRecruitingNCT06340230Phase 2
• Clinical Study of High-intensity Focused Ultrasound Tumor Treatment System(Super Knife) in the Treatment of Breast CancerRecruitingNCT06210529Not applicable
• Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingNCT06202313Phase 2
• Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBCRecruitingNCT06165900Phase 2
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2
• A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsRecruitingNCT05635487Phase 2
• Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast CancerRecruitingNCT05346510Not applicable
• The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.RecruitingNCT05263570
• Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant ChemotherapyRecruitingNCT05241119Not applicable
• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2
• Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer PatientsRecruitingNCT04983121Phase 2
• Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT04973319Phase 3
• Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyRecruitingNCT04476485
• Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCTRecruitingNCT04137653Phase 3
• Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant ChemotherapyNot yet recruitingNCT04137640Phase 4
• Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerRecruitingNCT04136782Phase 4
• Circulating Tumor Cell Detection in Patients With Luminal A Breast CancerRecruitingNCT04065321
• DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the BreastRecruitingNCT04052893Not applicable
• A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast CancerStatus unknownNCT05483439Phase 2
• Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BCStatus unknownNCT05400993Phase 2
• Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast CancerStatus unknownNCT05253066Phase 2/3
• Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant TreatmentActive, not recruitingNCT05132790Not applicable
• Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialActive, not recruitingNCT04486911Phase 2
• CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast CancerStatus unknownNCT04059003
• Palbociclib Combined With an Aromatase Inhibitor in Breast CancerStatus unknownNCT04047758Phase 3
• Study on Bisphosphonates Targeting Triple-negative Breast CancerStatus unknownNCT04045522